Principal Financial Group Inc. Trims Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Principal Financial Group Inc. decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 25.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 448,087 shares of the biopharmaceutical company's stock after selling 154,971 shares during the period. Principal Financial Group Inc. owned 0.35% of Halozyme Therapeutics worth $25,649,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. TD Asset Management Inc grew its holdings in Halozyme Therapeutics by 28.1% during the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company's stock worth $103,379,000 after acquiring an additional 557,350 shares during the period. Boston Trust Walden Corp bought a new stake in Halozyme Therapeutics in the second quarter worth approximately $23,211,000. CANADA LIFE ASSURANCE Co lifted its stake in Halozyme Therapeutics by 29.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company's stock valued at $5,321,000 after buying an additional 29,845 shares during the period. Swedbank AB bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $13,927,000. Finally, Mizuho Markets Americas LLC grew its position in shares of Halozyme Therapeutics by 2.2% during the 1st quarter. Mizuho Markets Americas LLC now owns 456,636 shares of the biopharmaceutical company's stock worth $18,576,000 after buying an additional 9,975 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total value of $620,300.00. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,778,084.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold a total of 70,000 shares of company stock worth $4,042,500 over the last three months. 2.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

HALO has been the subject of several research reports. TD Cowen lifted their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. HC Wainwright boosted their price objective on Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a "buy" rating in a report on Friday, November 1st. Finally, Benchmark restated a "buy" rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $61.11.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO traded down $0.75 during trading on Wednesday, reaching $58.86. The company's stock had a trading volume of 414,598 shares, compared to its average volume of 1,285,900. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The firm has a market cap of $7.49 billion, a price-to-earnings ratio of 19.48, a price-to-earnings-growth ratio of 0.55 and a beta of 1.29. The firm has a 50 day moving average of $56.53 and a 200-day moving average of $53.18. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.